We are evaluating strategies to enhance the in vivo pro-CD2/CD28 chimeric receptor was introduced into CTLL.2 liferation and function of adoptively transferred antigencells via retrovirus infection and was shown to be specific T cells. Although the CD28 costimulatory pathway expressed on the cell surface. By monitoring early and late is important for T cell activation and proliferation, the components of the CD28 signaling pathway, the chimeric expression of the ligands for CD28 is highly restricted. We receptor was demonstrated to trigger the CD28 pathway in have generated a chimeric receptor composed of the sigresponse to CD2 cross-linking. The possible utility of the naling domains of CD28 and the extracellular domain of CD2/CD28 chimeric receptor for adoptive immunotherapy CD2 which binds the widely expressed ligand CD58. The is discussed.
Introduction to sustain clonal expansion and establish immunologic The adoptive transfer of in vitro expanded lymphokine memory. activated killer cells (LAK), tumor infiltrating lympho-
A strength of signal theory has been proposed, sugcytes (TILs) and cytotoxic T lymphocytes (CTL) has been gesting a role for CD28 in the activation of T cells. 10 This demonstrated to mediate tumor regression or resistance model of costimulation proposes that under conditions to certain infectious diseases. 1, 2 However, optimal T cell of low antigen density, CD28 signaling is critical for T proliferation and cytotoxic function of adoptively transcell activation, expansion and cytokine production. When ferred T cells requires systemic administration of IL-2 antigen density is high, however, CD28 signaling may be which is associated with severe toxicity. 3 In addition, dispensable. Consistent with this hypothesis, recent large numbers of adoptively transferred T cells are reports demonstrate that CD28 costimulation signifirequired for therapeutic efficacy which may severely cantly reduces the number of occupied TCRs required to impact the commercialization of such therapies. We are induce T cell activation. 12, 13 developing strategies to enhance the in vivo proliferation In the past several years a variety of tumor antigens and function of antigen-specific CTL clones. Such have been described 14 suggesting that spontaneous modified T cells will reduce the number of adoptively tumors which appear to be non-immunogenic can serve transferred CTLs required for clinical significance and as targets for T cell responses. Numerous factors includeliminate the need for large systemic doses of IL-2.
ing lack of costimulation have been implicated to contribThe activation and proliferation of T cells requires mulute to the escape of tumors from immune surveiltiple signals. Engagement of the T cell receptor (TCR) lance. 15, 16 Lack of costimulation may also impair the alone is insufficient to fully activate T cells and can result function of adoptively transferred T cells by increasing in induction of anergy. A second signal or costimulation the antigen density requirements for T cell activation and is required to induce optimal T cell proliferation and limiting clonal expansion. Two ligands for CD28 have cytokine secretion. [4] [5] [6] CD28 has been demonstrated to fulbeen described, B7-1 17 and B7-2, 18, 19 which are members fill the costimulatory requirement and play an important of the immunoglobulin gene superfamily. The expression role in the activation and proliferation of T cells. Stimuof these ligands is highly restricted to professional antilation of T cells through the TCR and CD28 results in T gen presenting cells 10 and absent from the majority of cell proliferation and increased expression of a wide vartumors. These observations led to the development of iety of genes including IL-2.
7-10 CD28 signaling has also costimulation-based tumor vaccines. Numerous studies been shown to induce cell survival genes including Bclhave demonstrated that the introduction of B7-1 and/or X L and thus may play an important role in protecting T B7-2 into a variety of murine tumors results in rejection cells from apoptosis. 11 The induction of cell survival of the modified tumor and in some cases protects against genes suggests that in addition to the important role future challenge with unmodified tumor. 9, 20, 21 Tumor clearance and protection against future challenge has been demonstrated to be mediated by CD8 + T cells. While this approach has provided encouraging results, it is not An alternative strategy is to modify antigen-specific T at levels detectable by both methods. One clone (clone 27) which expressed high levels of CD2/CD28 and mCD3 cells such that the CD28 costimulatory pathway is triggered within a B7-negative environment. To that end, we levels similar to the parental ( Figure 2 ) was expanded and used in all analyses. The CTLL.2 parental cells and have generated a chimeric receptor composed of the extracellular domain of CD2 and the transmembrane and clone 27 do not express mCD28 at levels detectable by flow cytometry (Figure 2 ). The Western blot reveals that cytoplasmic domains of CD28. CD2 is a glycoprotein expressed on T cells and has been implicated to improve CD2/CD28 migrates as heterogeneous-sized bands ranging in size from 35 to 50 kDa ( Figure 2 ). Endogenous adhesion between T cells and target cells as well as deliver an activation signal. 22 The ligand for CD2 is CD58 hCD2 also displays size heterogeneity ranging from 50 to 65 kDa. This heterogeneity in size is apparently due to which, unlike B7-1 or B7-2, is expressed on all cell types in humans. 23 We present preliminary data on the differing levels of glycosylation (Ref. 25 and data not shown). We have observed that only the slower migrat-CD2/CD28 chimeric receptor which demonstrate that in CTLL.2 cells the CD2/CD28 chimeric receptor can trigger ing CD2/CD28 species is expressed on the cell surface (data not shown). the CD28 signaling pathway and induce responses associated with T cell activation and proliferation.
Association of p85 subunit of PI3-kinase with CD2/CD28
Results
To determine if the CD2/CD28 chimeric receptor was capable of triggering the CD28 signal, two assays were Generation of the CD2/CD28 chimeric receptor performed to examine events associated with CD28 sigThe extracellular domain of hCD2 and the transmemnaling. Phosphatidylinositol 3-kinase (PI3-kinase) is a brane and cytoplasmic domains of hCD28 were amplified ubiquitously expressed heterodimeric lipid kinase which by PCR and cloned into a retroviral vector under the conis activated by most protein tyrosine kinase-dependent trol of the MMLV LTR. The vector also contains an internal ribosome entry site (IRES) followed by the HYTK gene which permits selection in the presence of hygromycin B (see Materials and methods and Figure 1 ). A high titer PA317 viral producer line was generated which contained a single intact provirus and expressed CD2/CD28 (data not shown).
Retroviral infection of CTLL.2 and expression of CD2/CD28
CTLL.2 cells are a murine IL-2-dependent T cell line. 24 CTLL.2 cells were infected with the CD2/CD28 containing retrovirus by cocultivation with irradiated viral producer cells and selected in the presence of 300 U/ml hygromycin B. Drug-resistant clones were screened initially by PCR for the hygromycin phosphotransferase gene. Subsequently, Southern blots demonstrated the clones contained a single intact provirus (data not shown).
Expression of the CD2/CD28 chimeric receptor by the drug-resistant clones was determined by flow cytometry and Western blot analyses for hCD2. Greater than 50% of the drug-resistant CTLL.2 clones expressed CD2/CD28 receptors. 26 The p85 subunit of PI3-kinase contains two whether signaling through CD2/CD28 and the TCR could induce Bcl-X L expression. CTLL.2 parental and scr homology domains which can associate with a tyrosine phosphorylated YMXM domain. Several groups clone 27 cells were stimulated with 500 ng/ml antimCD3, 10 g/ml anti-hCD2 or a combination of the two. have demonstrated that CD28 cross-linking results in the rapid association of the p85 subunit with the YMNM Cells were incubated 20 h following stimulation and Bcl-X L expression assessed by Western blot. Bcl-X L motif within the cytoplasmic domain of CD28 27, 28 and is believed to be one of the earliest signaling events in the expression was not detected in either unstimulated parental or clone 27 cells (Figure 4 ). Parental and clone 27 CD28 signaling pathway.
We examined if p85 could associate with the cells stimulated with anti-hCD2 alone did not induce Bcl-X L while stimulation with anti-mCD3 alone induced low CD2/CD28 chimeric receptor following cross-linking with anti-hCD2. CTLL.2 cells are negative for mCD28 so levels of Bcl-X L (Figure 4) . The combination of anti-mCD3 and anti-hCD2 stimulation induced Bcl-X L in parental EL-4 cells were used as a positive control for the immunoprecipitation and Western blot. Immunoprecipitcells to the level seen with anti-mCD3 alone. However, in clone 27 cells the combination induced high levels of ation of CD28 from EL-4 cells co-immunoprecipitated low levels of the p85 subunit of PI3-kinase (Figure 3) .
Bcl-X L expression. Thus, TCR and CD2/CD28 crosslinking modulated expression of Bcl-X L as previously Cross-linking of EL-4 cells with anti-mCD28 before immunoprecipitation significantly increased co-immunodemonstrated for TCR and CD28 cross-linking. This result demonstrates that CD2/CD28 is capable of providprecipitation of p85 (Figure 3 ) which is consistent with previously published results. 27, 28 The mAb 35.1 recoging CD28 costimulation in conjunction with signaling through the TCR. nizes an epitope on the extracellular domain of hCD2 and thus recognizes CD2/CD28. Immunoprecipitation with mAb 35.1 resulted in co-immunoprecipitation of p85 at are believed to increase avidity between T cells and APCs Cross-linking with mAb 35.1 before immunoprecipitation and are capable of signaling in response to the appropof hCD2 resulted in high levels of p85 co-immunoprecipriate ligands. 30,31 However, the signaling pathways itation with clone 27 cells but not parental CTLL.2 cells initiated by these receptors are redundant to that initiated ( Figure 3) . Thus, under the appropriate stimulation conby the TCR and thus, their role in T cell activation is to ditions, p85 co-immunoprecipitated with CD2/CD28 as augment the TCR signal. 32 CD28, however, has been with endogenous CD28. This result demonstrates that the demonstrated to play an important role in T cell actifirst known step of the CD28 signaling pathway vation and proliferation. The observation that the CD28 is initiated by CD2/CD28 in response to anti-hCD2 signaling pathway resulted in cyclosporin A and FK506-cross-linking.
resistant IL-2 gene expression demonstrated the CD28 signal to be biochemically distinct from the signaling Induction of Bcl-X L expression in CD2/CD28-infected pathway initiated by the TCR.
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CTLL.2 cells
Due to the highly restricted expression of the ligands The association of p85 with CD2/CD28 represents an for CD28, we have generated a chimeric receptor capable early event in the CD28 signaling pathway. The compoof triggering this important costimulatory signal in nents of the CD28 signaling pathway are not well characterized but CD28 signaling modulates expression of a large number of genes through stabilization of mRNA and transcriptional up-regulation. 10, 29 One such gene is Bcl-X L which plays an important role in protecting T cells from apoptosis. Bcl-X L is not expressed in resting T cells but can be induced in T cells by sub-optimal anti-CD3 stimulation plus anti-CD28 stimulation. 11 We tested environments lacking B7 expression. The chimeric cillin, and 50 mg/ml streptomycin. ⌿2 37 and PA317 cells 38 were cultured in DMEM supplemented with 10% receptor contains the ligand binding domain from CD2 and the transmembrane and signaling domains from fetal calf serum, 2 mm l-glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin. CD28. We have demonstrated that the chimeric receptor triggers the CD28 signaling pathway in response to hCD2
Generation of CD2/CD28 chimeric receptor cross-linking.
The extracellular domain of hCD2 (cDNA a gift from Currently, we are modifying antigen-specific CD8 + T Brian Seed, Massachusetts General Hospital) and the cell clones directed against tumor or viral antigens for transmembrane and cytoplasmic domains of hCD28 use in adoptive immunotherapy with the CD2/CD28
(cDNA a gift from Craig Thompson, University of chimeric receptor. A number of issues need to be Chicago) were amplified by PCR. Primers were utilized addressed to determine if the CD2/CD28 chimeric recepto amplify amino acids −19 to 190 of CD2 39 and amino tor will be useful for adoptive immunotherapy. One acids 136 to 202 of CD28. 40 The amplified fragments were important issue concerns the response of previously actiligated in a SK vector (Stratagene, La Jolla, CA, USA). vated T cell clones to CD28 costimulation. In our hands
The CD2/CD28 chimeric receptor was subsequently subantigen-specific CD8
+ clones do respond to stimulation cloned into a retroviral vector under the transcriptional through the TCR and CD28 as determined by prolifercontrol of the MMLV LTR. Immediately downstream of ation assays and IL-2 secretion (data not shown). Thus, the CD2/CD28 chimeric receptor is an EMCV internal we anticipate that CD2/CD28 will have a functional ribosome entry site (IRES) followed by a HYTK gene impact on the modified T cell clones. In response to CD58 which permits positive selection on hygromycin B and and the appropriate antigen, modified T cells will initiate negative selection on ganciclovir. 41 three signaling pathways. Antigen will provide TCR signaling while CD58 will trigger both the CD2 pathway Generation of CD2/CD28 and retroviral producer line via endogenous CD2 and the CD28 pathway through the Retroviral producer lines were generated by transient CD2/CD28 chimeric receptor. The signaling pathways of transfection of ⌿2 cells followed by transinfection of CD2 and CD28 have been shown to be synergistic with PA317 cells as previously described. 41 Clones were respect to T cell activation and proliferation in vitro 34, 35 expanded in the presence of 300 U/ml hygromycin B and Li et al 36 have demonstrated similar results in vivo in (Calbiochem, La Jolla, CA, USA). Viral producer lines a tumor rejection model. Introduction of the ligands for were characterized for titer on NIH 3T3 cells and South-CD2 and CD28 individually or together in two poorly ern blot analyses were performed to determine copy immunogenic murine tumors resulted in a significant number and viral integrity. A high titer viral producer immune response only when both ligands were present. 36 line containing a single intact provirus was used for Our approach to provide costimulation is to modify infection of CTLL.2 cells. antigen-specific CTL rather than the target cells. By this strategy, large numbers of modified CTLs capable of Retroviral infection of CTLL.2 cells enhanced reactivity to all target cells can be delivered via Six-well cluster dishes were seeded with 2.5 × 10 5 PA317 adoptive immunotherapy. This should provide a signifi-CD2/CD28 viral producer cells in 2.5 ml of complete cant advantage over approaches which modify only a medium. Cells were grown to 75% confluency and small percentage of target cells by the addition of B7-1 irradiated at 30 Gy. Actively proliferating CTLL.2 cells or B7-2.
were added to the producer cells in 2.5 ml of complete To achieve activation and proliferation of CD2/CD28 medium supplemented with 30 g/ml DEAEmodified T cells, the target cells must express the approdextran (Sigma, St Louis, MO, USA). The CTLL.2 cells priate antigen in the context of MHC class I and CD58.
were cultivated in the presence of the irradiated viral pro-CD58 is expressed on all cell types and we have examducer cells for 20 h. CTLL.2 cells were harvested and ined several primary tumors and tumor-derived cells replated to eliminate contaminating viral producing cells lines and have found all to express CD58 and MHC class followed by cloning at 10 000 cells per well in 96-well flat-I (Table 1) . Therefore, due to the signals delivered by bottom plates containing 200 l IMDM complete medium CD2/CD28 and endogenous CD2, modified CTLs should supplemented with 300 U/ml hygromycin B. be activated via a larger variety of antigen expressing cells (ie low antigen density). In addition to decreasing Flow cytometry requirements for activation, the induction of Bcl-X L by mCD3, mCD28 and hCD2/CD28 expression was moni-CD2/CD28 stimulation may act to increase CTL lontored by immunofluorescence staining. 1 × 10 6 Cells in gevity by protecting cells from apoptosis. It is anticipated 100 l buffer were incubated with anti-mCD3-FITC that these phenotypic changes will reduce the number of (Pharmingen, San Diego, CA, USA), anti-mCD28 adoptively transferred CTLs required for clinical efficacy (Pharmingen) or 20 l of anti-hCD2 hybridoma superand eliminate the need for large systemic doses of IL-2.
natant (ATCC HB 195; Rockville, MD, USA) for 20 min at 4°C. Cells were washed twice. The cells stained with anti-mCD28 or anti-hCD2 were incubated with goat anti-
Materials and methods
hamster IgG-FITC or goat anti-mouse IgG-FITC (Cappel, Durham, NC, USA) respectively. After incubation, cells Cells were washed and analyzed on a Becton Dickinson FAC-CTLL.2 cells 24 were cultured in IMDM supplemented scan (San Jose, CA, USA). with 10% heat inactivated fetal calf serum, 15 U/ml IL-2 (Chiron, Emeryville, CA, USA), 1 × MEM non-essential CD2 Western blot Whole cell lysates were resolved on 10% polyacrylamide amino acids, 1 mm sodium pyruvate, 5 m 2-mercaptoethanol, 10 mm Hepes, 2 mm l-glutamine, 50 U/ml penigels and transferred to Immobilon P (Millipore, Bedford, MA, USA). The membrane was incubated with media acrylamide gradient gel, and transferred to Immobilon P. The membrane was incubated in the presence of anti-Bclsupernatant from HB195 (ATCC) diluted 1:5 containing anti-hCD2 followed by goat anti-mouse IgG diluted X L (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:1000 followed by goat anti-mouse Ig (Cappel) 1:5000 (Cappel). CD2 was visualized using enhanced chemiluminescence (ECL) detection reagents diluted 1:5000. Bcl-X L was visualized by ECL. (Amersham, Arlington Heights, IL, USA).
